

## Taxotere MDL swells to 700-plus lawsuits

SAN DIEGO, CALIFORNIA, USA, January 25, 2017 /EINPresswire.com/ --The number of Taxotere hair loss lawsuits skyrocketed between December and January.

The number of cases nearly tripled from just over 260 to more than 700 during the holiday season. This sudden spike comes three months after federal Taxotere lawsuits were <u>consolidated</u> into a multidistrict litigation (MDL).

Taxotere is a chemotherapy drug widely used to treat breast cancer. It is manufactured by the U.S. division of French pharmaceutical company Sanofi.

The drug is highly potent and, like many chemotherapy medications, can lead to hair loss. What makes Taxotere different from other chemotherapy drugs is that sometimes hair loss is permanent.



The Taxotere label used to indicate that

roughly 3% of patients could experience permanent alopecia, or permanent hair loss, when using the drug. But studies and surveys have shown that the percentage could be as high as 6% to 16%.

Today, the Taxotere label suggests the frequency of permanent hair loss is "not known."

If the nearly 300% surge in Taxotere lawsuits is any indication, many more cases could be filed in the coming months as the litigation moves forward." *Schmidt National Law Group* 

"

Mississippi resident Theresa Snowden is one of the many women who used Taxotere to treat breast cancer and now suffers from permanent hair loss. She filed a lawsuit against Sanofi on Dec. 22 claiming the company designed a defective product and failed to warn about its potential risks.

Theresa was diagnosed with breast cancer in April 2013 and was prescribed Taxotere by her oncologist for treatment, according to court documents.

It wasn't until September 2016 that Theresa learned of the link between Taxotere and permanent hair loss.

Theresa's lawsuit is one of 705 currently pending in the Eastern District of Louisiana as part of the

Taxotere MDL.

If the nearly 300% surge in Taxotere lawsuits is any indication, many more cases could be filed in the coming months as the litigation moves forward.

Taxotere patients who experienced permanent hair loss may be able to file lawsuits of their own.

Schmidt National Law Group is currently seeking claimants and is in the process of filing claims related to Taxotere and permanent hair loss. Contact us today at 1-800-214-1010 or visit our <u>website</u> to learn more.

The case is Snowden vs. Sanofi S.A. et al. (1:16-cv-00440) in the U.S. District Court for the Southern District of Mississippi and In Re: Taxotere (Docetaxel) Products Liability Litigation in the U.S. District Court for the Eastern District of Louisiana.

About Schmidt National Law Group

Schmidt National Law Group is a personal injury firm located in San Diego, Calif. Its attorneys represent victims of all types of injuries, including those harmed by pharmaceutical drugs and medical devices.

In his 30 years as a trial attorney, Martin Schmidt of Schmidt National Law Group has represented countless victims of defective drugs and medical devices, as well as those injured in personal injury accidents. Martin Schmidt has been recognized as a leading personal injury attorney, having been chosen as one of the "Top 100 Trial Lawyers" by the American Association for Justice in 2015 and 2016.

Contact Us

Schmidt National Law Group http://www.nationalinjuryhelp.com/ 4241 Jutland Drive, Suite 200, San Diego CA, 92117 (800) 214-1010

Melissa Beltz Schmidt National Law Group 800-214-1010 Ext. 370 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.